These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33324397)

  • 1. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
    Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
    Front Immunol; 2020; 11():572172. PubMed ID: 33324397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
    Ellingsen EB; Aamdal E; Guren T; Lilleby W; Brunsvig PF; Mangsbo SM; Aamdal S; Hovig E; Mensali N; Gaudernack G; Inderberg EM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
    Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
    Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
    Aamdal E; Inderberg EM; Ellingsen EB; Rasch W; Brunsvig PF; Aamdal S; Heintz KM; Vodák D; Nakken S; Hovig E; Nyakas M; Guren TK; Gaudernack G
    Front Immunol; 2021; 12():663865. PubMed ID: 34046035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
    Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
    Sebastian M; Schröder A; Scheel B; Hong HS; Muth A; von Boehmer L; Zippelius A; Mayer F; Reck M; Atanackovic D; Thomas M; Schneller F; Stöhlmacher J; Bernhard H; Gröschel A; Lander T; Probst J; Strack T; Wiegand V; Gnad-Vogt U; Kallen KJ; Hoerr I; von der Muelbe F; Fotin-Mleczek M; Knuth A; Koch SD
    Cancer Immunol Immunother; 2019 May; 68(5):799-812. PubMed ID: 30770959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
    Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
    Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
    Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
    Front Immunol; 2018; 9():2145. PubMed ID: 30283461
    [No Abstract]   [Full Text] [Related]  

  • 10. Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model.
    Ibrahim EIK; Ellingsen EB; Mangsbo SM; Friberg LE
    Int Immunopharmacol; 2024 Jan; 126():111225. PubMed ID: 37988911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
    Hansen GL; Gaudernack G; Brunsvig PF; Cvancarova M; Kyte JA
    Cancer Immunol Immunother; 2015 Dec; 64(12):1609-21. PubMed ID: 26498005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
    Gridelli C; Ciuleanu T; Domine M; Szczesna A; Bover I; Cobo M; Kentepozidis N; Zarogoulidis K; Kalofonos C; Kazarnowisz A; Korozan M; de Las Penas R; Majem M; Chella A; Griesinger F; Bournakis E; Sadjadian P; Kotsakis A; Chinet T; Syrigos KN; Correale P; Gallou C; Jamet JM; Vetsika EK; Kosmatopoulos K; Georgoulias V;
    Br J Cancer; 2020 May; 122(10):1461-1466. PubMed ID: 32210365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
    Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
    Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
    J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.